華潤雙鶴(600062.SH):擬投資4.01億元用於研發中心(次渠)建設項目
格隆匯 12 月 10日丨華潤雙鶴(600062.SH)公佈,公司第八屆董事會第二十二次會議決議,審議通過關於華潤雙鶴研發中心(次渠)建設項目的議案;
根據公司整體戰略規劃,為統籌公司研發資源,提升研發效率,推動公司產品驅動增長以及綜合考慮未來研發、生產經營配套保障,同意公司投資40135.44萬元(僅限固定資產投資,不含研發工藝及檢測設備等)用於華潤雙鶴研發中心(次渠)建設項目;授權公司經營層負責組織實施本次建設項目相關事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.